ESC 365 - What is the clinical impact of hyperkalaemia?

HFA Premium Access

What is the clinical impact of hyperkalaemia?

Session: The hyperkalaemia challenge in heart failure: what is the role of novel agents?

Topic: Treatment

Speaker: Professor C. Linde (Stockholm, SE)

Sponsored by AstraZeneca

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Cecilia Marianne Linde

Karolinska Institute, Stockholm (Sweden)

68 presentations

6 followers

4 more presentations in this session

Chair's introduction - The hyperkalaemia challenge in heart failure: what is the role of novel agents?

Speaker: Professor A. Stewart Coats (Sydney, AU)

Hyperkalaemia: a barrier to optimal management of patients with heart failure?

Speaker: Professor A. Stewart Coats (Sydney, AU)

Solving the K+ challenge in heart failure: are novel K+ binders the answer?

Speaker: Professor M. Volterrani (Rome, IT)

Clinical experience with novel K+ binders: what are the opportunities and challenges?

Speaker: Professor C. Linde (Stockholm, SE) Professor A. Stewart Coats (Sydney, AU) Professor M. Volterrani (Rome, IT)

Access the full session

The hyperkalaemia challenge in heart failure: what is the role of novel agents?

Speakers: Professor C. Linde, Professor A. Stewart Coats, Professor A. Stewart Coats, Professor M. Volterrani, Professor C. Linde...

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources